

Will the Approval of Inflectra be a Biosimilar Adoption Tipping Point?

June 9, 2016

ATTORNEYS

Ropka, PhD, Stacie

Nicole Gray

BioPharma Dive

Axinn counsel Stacie Ropka was quoted in the *BioPharma Dive* article, “Will the Approval of Inflectra be a Biosimilar Adoption Tipping Point?”

Click [here](#) to access the article.